Pathogen reduction of blood components (Q37207560)

18 August 2017

1 reference

title

Pathogen reduction of blood components (English)

1 reference

18 August 2017

0 references

Bjarte G Solheim

1

1 reference

18 August 2017

3 July 2008

1 reference

Transfusion and Apheresis Science

18 August 2017

1 reference

18 August 2017

39

1 reference

18 August 2017

75-82

1 reference

18 August 2017

1

1 reference

FDA approach to evaluation of pathogen reduction technology

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Pathogen inactivation techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Update on pathogen reduction technology for therapeutic plasma: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Pathogen-reduction systems for blood components: the current position and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Solvent/detergent-treated plasma: composition, efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Composition, efficacy, and safety of S/D-treated plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2008.05.003

10.1016/J.TRANSCI.2008.05.003

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18602343